What are the causes, clinical features, diagnostic work‑up, and management strategies for cerebral palsy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 29, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Cerebral Palsy: Causes, Features, Diagnosis and Management

Definition and Epidemiology

Cerebral palsy is a group of permanent disorders of movement and posture development, causing activity limitation, attributed to non-progressive disturbances in the developing fetal or infant brain 1. It is the most common physical disability in childhood, with a prevalence of 2.1 per 1000 live births in high-income countries 1.

Causes and Risk Factors

The complete causal pathway remains unclear in approximately 80% of cases, but identifiable risk factors exist across multiple time periods 1:

Preconception Risk Factors 1

  • History of stillbirths or miscarriages
  • Low socioeconomic status
  • Assisted reproduction
  • Abnormal genetic copy number variations

Pregnancy Risk Factors 1

  • Prematurity (most frequent risk factor)
  • Low birth weight
  • Genetic abnormalities and birth defects
  • Multiple gestations
  • Male sex
  • Maternal thyroid disease or preeclampsia
  • Intrauterine infections
  • Intrauterine growth restriction
  • Substance abuse

Perinatal and Postnatal Factors

  • Hypoxic-ischemic encephalopathy (birth asphyxia accounts for <10% of cases) 2
  • Intracerebral hemorrhage in preterm infants
  • Periventricular leukomalacia

Genetic Component

Emerging evidence shows that 14% of cases have a genetic component 1. Recent meta-analysis demonstrates that exome sequencing yields a diagnostic rate of 31.1% overall, with 34.8% in pediatric populations 2. This diagnostic yield is similar to other neurodevelopmental disorders for which exome sequencing is recommended as standard of care 2.

Clinical Features

Motor Types (emerge and evolve during first 2 years) 1

Spasticity (85-91%) - Most common type

  • Unilateral (hemiplegia): 38% of cases
  • Bilateral diplegia: 37% (lower limbs more affected than upper)
  • Quadriplegia: 24% (all 4 limbs and trunk)

Dyskinesia (4-7%) - Includes dystonia and athetosis, affects all 4 limbs

Ataxia (4-6%) - Affects all 4 limbs

Hypotonia (2%) - Not classified in all countries

Common Comorbidities 1

  • Chronic pain: 75%
  • Epilepsy: 35%
  • Intellectual disability: 49%
  • Musculoskeletal problems (hip displacement): 28%
  • Behavioral disorders: 26%
  • Sleep disorders: 23%
  • Functional blindness: 11%
  • Hearing impairment: 4%

Functional Prognosis in High-Income Countries 1

  • 2 in 3 will walk
  • 3 in 4 will talk
  • 1 in 2 will have normal intelligence

Diagnosis

Early diagnosis is now possible before 6 months corrected age using a combination of standardized tools with strong predictive validity 1. The traditional "silent period" concept is outdated 1.

Diagnostic Approach: Two Pathways 1

Pathway 1: Newborn-Detectable Risks (Before 5 months corrected age)

  • For infants with identifiable high-risk indicators at birth (prematurity, encephalopathy, genetic abnormalities, seizures)

Most predictive tools before 5 months corrected age 1:

  1. Neonatal MRI: 86-89% sensitivity
  2. Prechtl Qualitative Assessment of General Movements: 98% sensitivity
  3. Hammersmith Infant Neurological Examination (HINE): 90% sensitivity

Pathway 2: Infant-Detectable Risks (After 5 months corrected age)

  • For infants with apparently uneventful pregnancy/labor where delayed motor milestones are first noticed

Most predictive tools after 5 months corrected age 1:

  1. MRI: 86-89% sensitivity (where safe and feasible)
  2. HINE: 90% sensitivity
  3. Developmental Assessment of Young Children: 83% C index

Diagnostic Criteria for "High Risk of Cerebral Palsy" 1

Essential Criterion (Required):

  • Motor dysfunction: Reduced or neurologically abnormal movement quality (absent fidgety general movements, early hand asymmetry, suboptimal HINE scores, head lag, not sitting, inability to grasp when age-appropriate)

Plus at least ONE of the following:

  1. Abnormal neuroimaging - Most predictive MRI patterns 1:

    • White matter injury (cystic periventricular leukomalacia, periventricular hemorrhagic infarctions): 56%
    • Cortical/deep gray matter lesions (basal ganglia, thalamus, watershed injury, stroke): 18%
    • Brain maldevelopments (lissencephaly, pachygyria, cortical dysplasia, polymicrogyria, schizencephaly): 9%

  2. Clinical history indicating risk (see risk factors above)

Important Diagnostic Caveat 1

In milder presentations (especially unilateral cerebral palsy), infants may score within normal range on standardized motor assessments while still displaying abnormal movements. For example, an infant with hemiplegia might complete fine-motor tasks one-handed but achieve a "normal" score. Assessment must be performed by professionals skilled at distinguishing atypical from typical movement variation.

Additional Diagnostic Testing

Genetic testing should be considered given the 31.1% diagnostic yield of exome sequencing 2. The yield is higher (42.1%) when exclusion criteria are used for patient selection 2.

MRI is indicated to delineate brain lesions and identify congenital malformations 3.

Tests for inborn errors of metabolism are indicated to identify specific treatable disorders 3.

Management

Management requires sustained collaboration among multiple disciplines due to the numerous associated medical conditions 3. The focus is on maximizing function and participation while minimizing factors that worsen the condition.

Early Intervention

Prompt referral to cerebral palsy-specific early intervention is critical to optimize infant motor and cognitive plasticity, prevent secondary complications, and enhance caregiver well-being 1. This should occur immediately upon diagnosis or "high risk" designation, not delayed until definitive diagnosis.

Spasticity Management 4

  • Intramuscular onabotulinumtoxinA (botulinum toxin)
  • Systemic and intrathecal muscle relaxants
  • Selective dorsal rhizotomy (surgical option)
  • Physical and occupational therapies

Comorbidity Management 4

Address throughout lifespan:

  • Epilepsy management (often drug-resistant)
  • Cognitive dysfunction support
  • Prevention and management of pressure ulcers
  • Osteoporosis prevention
  • Behavioral/emotional problems
  • Speech and hearing impairment interventions
  • Nutritional support
  • Pain management
  • Dental care
  • Bowel and bladder continence
  • Orthopedic complications (hip dislocation, scoliosis)

Prevention Strategies 5

  • Magnesium sulfate during premature labor (reduces rate and severity) 6
  • Therapeutic hypothermia for high-risk neonates (cooling reduces rate and severity) 6
  • Antenatal steroids for mothers expected to deliver prematurely
  • 17alpha-progesterone to prolong pregnancy
  • Limiting multiple gestations from assisted reproductive technology
  • Caffeine for extremely low birth weight neonates

Key Clinical Pitfall

Do not wait until 12-24 months to diagnose cerebral palsy when standardized tools can predict risk before 6 months corrected age 1. Early diagnosis enables earlier intervention during the critical period of neuroplasticity, directly impacting long-term functional outcomes and quality of life.

References

3
Research

Cerebral palsy in children: A clinical practice review.

Current problems in pediatric and adolescent health care, 2024

4
Research

Cerebral Palsy: An Overview.

American family physician, 2020

5
Research

Diagnosis, treatment, and prevention of cerebral palsy.

Clinical obstetrics and gynecology, 2008

6
Research

Cerebral palsy.

Nature reviews. Disease primers, 2016

Related Questions

Should individuals with cerebral palsy be evaluated and managed by a specialist, such as a pediatric neurologist or physiatrist?
What ICD‑10 code should be used for ordering oral nutritional supplement (boost drinks) for a cerebral palsy patient who refuses solid foods?
What is the best treatment for agitation in a patient with cerebral palsy?
Is the dosing regimen of 10 sublingual drops taken up to three times daily, about 30 minutes before or after meals, appropriate for an adult patient with cerebral palsy?
What are head lag and tonic limbs in cerebral palsy?
In a farmer with depression, inflammatory bowel disease, asthma, Long QT syndrome, ADHD, childhood migraine, antiphospholipid syndrome, and fibromyalgia who suffered blunt head trauma two days ago (hit on the head by a goat and lifted a 120‑kg sheep) and now presents with persistent occipital headache and left posterior neck stiffness, what urgent imaging and medical management should be recommended, taking into account his contraindication to QT‑prolonging medications and lidocaine intolerance?
What are the current indications, dosing regimens, adverse effects, contraindications, pitfalls, benefits, and prescribing considerations for oral semaglutide (Rybelsus) and injectable semaglutide (Ozempic) in adults with type 2 diabetes and obesity, including cautions when combined with other medications?
Should systemic therapy be escalated for a patient with chronic graft‑versus‑host disease involving the oral cavity, skin and liver who is currently receiving ruxolitinib (Jakavi) 20 mg daily and budesonide mouthwash three times daily, with persistent oral ulceration, uncontrolled ocular disease despite optimized topical therapy, and an isolated γ‑GT elevation, and if so, which systemic agent should be added?
Is there any correlation between fenofibrate and the diet recommended for glucose‑6‑phosphate dehydrogenase (G6PD) deficiency?
In a 65-year-old diabetic male with a weeping foul ulcer at the nape and severe facial swelling limiting eye opening, who is receiving meropenem for cellulitis and has a serum creatinine of 1.8 mg/dL, should amikacin be replaced with levofloxacin and what levofloxacin dose is appropriate for his renal function?
What is the recommended dosage, indications, and contraindications for ezetimibe in adults?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.